Appointment of Nominated Adviser and Sole Broker | 11-Jun-2024 | 07:00 | RNS |
Posting of Annual Report and Notice of AGM | 31-May-2024 | 07:00 | RNS |
Successful Completion of First Cohort | 23-May-2024 | 07:00 | RNS |
Full Year Results | 30-Apr-2024 | 07:01 | RNS |
Board Change | 30-Apr-2024 | 07:00 | RNS |
Block listing Interim Return REPLACEMENT | 26-Apr-2024 | 09:51 | RNS |
Block Listing Six Monthly Return | 26-Apr-2024 | 07:00 | RNS |
Block Listing Application to AIM | 23-Apr-2024 | 09:43 | RNS |
Notice of Results | 23-Apr-2024 | 07:00 | RNS |
Issue of Equity and Total Voting Rights | 22-Apr-2024 | 12:14 | RNS |
Avacta Reports Data at the AACR Annual Meeting | 09-Apr-2024 | 17:00 | RNS |
AVA6000 Abstract Release by AACR | 08-Apr-2024 | 07:00 | RNS |
Update on AVA6000 Phase 1a Clinical Trial Progress | 21-Mar-2024 | 07:00 | RNS |
Result of General Meeting | 18-Mar-2024 | 13:26 | RNS |
Avacta Announces AVA6000 Poster at AACR | 06-Mar-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 40.25p |
Change Today | -0.50p |
% Change | -1.23 % |
52 Week High | 159.60p |
52 Week Low | 40.02p |
Volume | 1,003,068 |
Shares Issued | 359.04m |
Market Cap | £144.51m |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
16:52 | 32,027 @ 40.27p |
16:36 | 25,000 @ 40.28p |
16:18 | 3,770 @ 40.25p |
16:14 | 900 @ 40.10p |
16:14 | 287 @ 40.10p |
CFO | Tony Peter Gardiner |
CEO | Christina Coughlin |
You are here: research